Illana Gozes - Publications

Affiliations: 
Tel Aviv University, Tel Aviv-Yafo, Tel Aviv District, Israel 
Area:
biochemistry

192 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Pachima YI, Zhou LY, Lei P, Gozes I. Microtubule-Tau Interaction as a Therapeutic Target for Alzheimer's Disease. Journal of Molecular Neuroscience : Mn. PMID 26816082 DOI: 10.1007/s12031-016-0715-x  0.48
2016 Gozes I, Sragovich S, Schirer Y, Idan-Feldman A. D-SAL and NAP: Two Peptides Sharing a SIP Domain. Journal of Molecular Neuroscience : Mn. PMID 26816081 DOI: 10.1007/s12031-015-0701-8  0.48
2016 Amram N, Hacohen-Kleiman G, Sragovich S, Malishkevich A, Katz J, Touloumi O, Lagoudaki R, Grigoriadis NC, Giladi E, Yeheskel A, Pasmanik-Chor M, Jouroukhin Y, Gozes I. Sexual divergence in microtubule function: the novel intranasal microtubule targeting SKIP normalizes axonal transport and enhances memory Molecular Psychiatry. DOI: 10.1038/mp.2015.208  0.48
2015 Malishkevich A, Marshall GA, Schultz AP, Sperling RA, Aharon-Peretz J, Gozes I. Blood-Borne Activity-Dependent Neuroprotective Protein (ADNP) is Correlated with Premorbid Intelligence, Clinical Stage, and Alzheimer's Disease Biomarkers. Journal of Alzheimer's Disease : Jad. PMID 26639975 DOI: 10.3233/JAD-150799  0.48
2015 Gozes I, Ivashko-Pachima Y. ADNP: in search for molecular mechanisms and innovative therapeutic strategies for frontotemporal degeneration. Frontiers in Aging Neuroscience. 7: 205. PMID 26578950 DOI: 10.3389/fnagi.2015.00205  0.48
2015 Vaisburd S, Shemer Z, Yeheskel A, Giladi E, Gozes I. Risperidone and NAP protect cognition and normalize gene expression in a schizophrenia mouse model. Scientific Reports. 5: 16300. PMID 26553741 DOI: 10.1038/srep16300  0.48
2015 Kleiman GH, Barnea A, Gozes I. ADNP: A major autism mutated gene is differentially distributed (age and gender) in the songbird brain. Peptides. PMID 25895853 DOI: 10.1016/j.peptides.2015.04.008  0.48
2015 Malishkevich A, Amram N, Hacohen-Kleiman G, Magen I, Giladi E, Gozes I. Activity-dependent neuroprotective protein (ADNP) exhibits striking sexual dichotomy impacting on autistic and Alzheimer's pathologies. Translational Psychiatry. 5: e501. PMID 25646590 DOI: 10.1038/tp.2014.138  0.48
2015 Gozes I, Yeheskel A, Pasmanik-Chor M. Activity-dependent neuroprotective protein (ADNP): a case study for highly conserved chordata-specific genes shaping the brain and mutated in cancer. Journal of Alzheimer's Disease : Jad. 45: 57-73. PMID 25428252 DOI: 10.3233/JAD-142490  0.48
2015 Merenlender-Wagner A, Malishkevich A, Shemer Z, Udawela M, Gibbons A, Scarr E, Dean B, Levine J, Agam G, Gozes I. Autophagy has a key role in the pathophysiology of schizophrenia. Molecular Psychiatry. 20: 126-32. PMID 24365867 DOI: 10.1038/mp.2013.174  0.48
2015 Pennuto M, Greensmith L, Pradat PF, Sorarù G, Baniahmad A, Basso M, Cato A, Finsterer J, Fischbeck K, Fratta P, Gozes I, Jokela M, Pareyson D, Poletti A, Rinaldi C, et al. 210th ENMC International Workshop: Research and clinical management of patients with spinal and bulbar muscular atrophy, 27-29 March, 2015, Naarden, The Netherlands Neuromuscular Disorders. 25: 802-812. DOI: 10.1016/j.nmd.2015.06.462  0.48
2015 Malishkevich A, Leyk J, Goldbaum O, Richter-Landsberg C, Gozes I. ADNP/ADNP2 expression in oligodendrocytes: implication for myelin-related neurodevelopment Journal of Molecular Neuroscience. DOI: 10.1007/s12031-015-0640-4  0.48
2015 Gozes I, Baas PW, Richter-Landsberg C. International Meeting Molecular Neurodegeneration: News and Views in Molecular Neuroscience in Health and Disease. Delmenhorst, Germany, July 20–22, 2015 Journal of Molecular Neuroscience. DOI: 10.1007/s12031-015-0637-z  0.48
2015 Gozes I, Helsmoortel C, Vandeweyer G, Van der Aa N, Kooy F, Sermone SB. The Compassionate Side of Neuroscience: Tony Sermone’s Undiagnosed Genetic Journey—ADNP Mutation Journal of Molecular Neuroscience. 56: 751-757. DOI: 10.1007/s12031-015-0586-6  0.48
2014 Gozes I. Journal of molecular neuroscience: impacting our brains. Journal of Molecular Neuroscience : Mn. 54: 291-2. PMID 25330862 DOI: 10.1007/s12031-014-0444-y  0.48
2014 Korolkov VV, Allen S, Roberts CJ, Gozes I, Tendler SJ. Study of NAP adsorption and assembly on the surface of HOPG. Peptides. 62: 55-8. PMID 25278491 DOI: 10.1016/j.peptides.2014.09.017  0.48
2014 Oz S, Kapitansky O, Ivashco-Pachima Y, Malishkevich A, Giladi E, Skalka N, Rosin-Arbesfeld R, Mittelman L, Segev O, Hirsch JA, Gozes I. The NAP motif of activity-dependent neuroprotective protein (ADNP) regulates dendritic spines through microtubule end binding proteins. Molecular Psychiatry. 19: 1115-24. PMID 25178163 DOI: 10.1038/mp.2014.97  0.48
2014 Boxer AL, Lang AE, Grossman M, Knopman DS, Miller BL, Schneider LS, Doody RS, Lees A, Golbe LI, Williams DR, Corvol JC, Ludolph A, Burn D, Lorenzl S, Litvan I, ... ... Gozes I, et al. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. The Lancet. Neurology. 13: 676-85. PMID 24873720 DOI: 10.1016/S1474-4422(14)70088-2  0.48
2014 Magen I, Gozes I. Davunetide: Peptide therapeutic in neurological disorders. Current Medicinal Chemistry. 21: 2591-8. PMID 24533805  0.48
2014 Gozes I, Iram T, Maryanovsky E, Arviv C, Rozenberg L, Schirer Y, Giladi E, Furman-Assaf S. Novel tubulin and tau neuroprotective fragments sharing structural similarities with the drug candidate NAP (Davuentide). Journal of Alzheimer's Disease : Jad. 40: S23-36. PMID 24503616 DOI: 10.3233/JAD-131664  0.48
2014 Schirer Y, Malishkevich A, Ophir Y, Lewis J, Giladi E, Gozes I. Novel marker for the onset of frontotemporal dementia: early increase in activity-dependent neuroprotective protein (ADNP) in the face of Tau mutation. Plos One. 9: e87383. PMID 24489906 DOI: 10.1371/journal.pone.0087383  0.48
2014 Gozes I, Schirer Y, Idan-Feldman A, David M, Furman-Assaf S. NAP alpha-aminoisobutyric acid (IsoNAP). Journal of Molecular Neuroscience : Mn. 52: 1-9. PMID 24458740 DOI: 10.1007/s12031-013-0103-8  0.48
2014 Esteves AR, Gozes I, Cardoso SM. The rescue of microtubule-dependent traffic recovers mitochondrial function in Parkinson's disease. Biochimica Et Biophysica Acta. 1842: 7-21. PMID 24120997 DOI: 10.1016/j.bbadis.2013.10.003  0.48
2013 Alonso Adel C, ElAkkad E, Gong C, Liu F, Tanaka T, Kudo T, Tatebayashi Y, Pei J, Wang J, Khatoon S, Flory M, Ghetti B, Gozes I, Novak M, Novak M, et al. Inge Grundke-Iqbal, Ph.D. (1937–2012): the discoverer of the abnormal hyperphosphorylation of tau in Alzheimer’s disease. Journal of Molecular Neuroscience : Mn. 49: 430-5. PMID 24883456 DOI: 10.1007/s12031-012-9925-z  0.48
2013 Magen I, Gozes I. Microtubule-stabilizing peptides and small molecules protecting axonal transport and brain function: focus on davunetide (NAP). Neuropeptides. 47: 489-95. PMID 24210139 DOI: 10.1016/j.npep.2013.10.011  0.48
2013 Jouroukhin Y, Ostritsky R, Assaf Y, Pelled G, Giladi E, Gozes I. NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: protection against impairments in axonal transport. Neurobiology of Disease. 56: 79-94. PMID 23631872 DOI: 10.1016/j.nbd.2013.04.012  0.48
2013 Gozes I, Baas PW. Activity-dependent neuroprotective protein (adnp) and davunetide (nap) Handbook of Biologically Active Peptides. 1611-1618. DOI: 10.1016/B978-0-12-385095-9.00220-7  0.48
2013 Oz S, Gozes I. The cytoskeleton as a pharmacological target in neurodegenerative diseases Neuromethods. 79: 151-169. DOI: 10.1007/978-1-62703-266-7-8  0.48
2012 Oz S, Ivashko-Pachima Y, Gozes I. The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities. Plos One. 7: e51458. PMID 23272107 DOI: 10.1371/journal.pone.0051458  0.48
2012 Gozes I. Neuropeptide GPCRs in neuroendocrinology: the case of activity-dependent neuroprotective protein (ADNP). Frontiers in Endocrinology. 3: 134. PMID 23162535 DOI: 10.3389/fendo.2012.00134  0.48
2012 Dresner E, Malishkevich A, Arviv C, Leibman Barak S, Alon S, Ofir R, Gothilf Y, Gozes I. Novel evolutionary-conserved role for the activity-dependent neuroprotective protein (ADNP) family that is important for erythropoiesis. The Journal of Biological Chemistry. 287: 40173-85. PMID 23071114 DOI: 10.1074/jbc.M112.387027  0.48
2012 Jouroukhin Y, Ostritsky R, Gozes I. D-NAP prophylactic treatment in the SOD mutant mouse model of amyotrophic lateral sclerosis: review of discovery and treatment of tauopathy. Journal of Molecular Neuroscience : Mn. 48: 597-602. PMID 22956189 DOI: 10.1007/s12031-012-9882-6  0.48
2012 Idan-Feldman A, Ostritsky R, Gozes I. Tau and caspase 3 as targets for neuroprotection. International Journal of Alzheimer's Disease. 2012: 493670. PMID 22693678 DOI: 10.1155/2012/493670  0.48
2012 Gold M, Lorenzl S, Stewart AJ, Morimoto BH, Williams DR, Gozes I. Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy. Neuropsychiatric Disease and Treatment. 8: 85-93. PMID 22347799 DOI: 10.2147/NDT.S12518  0.48
2012 Harmar AJ, Fahrenkrug J, Gozes I, Laburthe M, May V, Pisegna JR, Vaudry D, Vaudry H, Waschek JA, Said SI. Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. British Journal of Pharmacology. 166: 4-17. PMID 22289055 DOI: 10.1111/j.1476-5381.2012.01871.x  0.48
2011 Gozes I. Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Current Pharmaceutical Design. 17: 3413-7. PMID 21902667 DOI: 10.2174/138161211798072553  0.48
2011 Idan-Feldman A, Schirer Y, Polyzoidou E, Touloumi O, Lagoudaki R, Grigoriadis NC, Gozes I. Davunetide (NAP) as a preventative treatment for central nervous system complications in a diabetes rat model. Neurobiology of Disease. 44: 327-39. PMID 21827858 DOI: 10.1016/j.nbd.2011.06.020  0.48
2011 Shiryaev N, Pikman R, Giladi E, Gozes I. Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects. Current Pharmaceutical Design. 17: 2603-12. PMID 21728979  0.48
2011 Gozes I. NAP (davunetide) provides functional and structural neuroprotection. Current Pharmaceutical Design. 17: 1040-4. PMID 21524250 DOI: 10.2174/138161211795589373  0.48
2011 Shioda S, Gozes I. VIP and PACAP: novel approaches to brain functions and neuroprotection. Current Pharmaceutical Design. 17: 961. PMID 21524249 DOI: 10.2174/138161211795589391  0.48
2011 Belokopytov M, Shulman S, Dubinsky G, Gozes I, Belkin M, Rosner M. Ameliorative effect of NAP on laser-induced retinal damage. Acta Ophthalmologica. 89: e126-31. PMID 21288307 DOI: 10.1111/j.1755-3768.2010.02041.x  0.48
2011 Fleming SM, Mulligan CK, Richter F, Mortazavi F, Lemesre V, Frias C, Zhu C, Stewart A, Gozes I, Morimoto B, Chesselet MF. A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions. Molecular and Cellular Neurosciences. 46: 597-606. PMID 21193046 DOI: 10.1016/j.mcn.2010.12.011  0.48
2011 Sokolowska P, Passemard S, Mok A, Schwendimann L, Gozes I, Gressens P. Neuroprotective effects of NAP against excitotoxic brain damage in the newborn mice: implications for cerebral palsy. Neuroscience. 173: 156-68. PMID 21073926 DOI: 10.1016/j.neuroscience.2010.10.074  0.48
2011 Gozes I. Microtubules, schizophrenia and cognitive behavior: preclinical development of davunetide (NAP) as a peptide-drug candidate. Peptides. 32: 428-31. PMID 21050875 DOI: 10.1016/j.peptides.2010.10.030  0.48
2011 Dresner E, Agam G, Gozes I. Activity-dependent neuroprotective protein (ADNP) expression level is correlated with the expression of the sister protein ADNP2: deregulation in schizophrenia. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 21: 355-61. PMID 20598862 DOI: 10.1016/j.euroneuro.2010.06.004  0.48
2010 Gozes I. Tau pathology: predictive diagnostics, targeted preventive and personalized medicine and application of advanced research in medical practice. The Epma Journal. 1: 305-16. PMID 23199066 DOI: 10.1007/s13167-010-0029-y  0.48
2010 Gozes I. VIP-PACAP 2010: my own perspective on modulation of cognitive and emotional behavior. Journal of Molecular Neuroscience : Mn. 42: 261-3. PMID 20922501 DOI: 10.1007/s12031-010-9456-4  0.48
2010 Gozes I. Tau pathology and future therapeutics. Current Alzheimer Research. 7: 685-96. PMID 20678069  0.48
2010 Shiryaev N, Jouroukhin Y, Gozes I. 3R tau expression modifies behavior in transgenic mice. Journal of Neuroscience Research. 88: 2727-35. PMID 20544828 DOI: 10.1002/jnr.22431  0.48
2010 Merenlender-Wagner A, Pikman R, Giladi E, Andrieux A, Gozes I. NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse--a microtubule-deficient model of schizophrenia. Peptides. 31: 1368-73. PMID 20417241 DOI: 10.1016/j.peptides.2010.04.011  0.48
2010 Fernandez-Montesinos R, Torres M, Baglietto-Vargas D, Gutierrez A, Gozes I, Vitorica J, Pozo D. Activity-dependent neuroprotective protein (ADNP) expression in the amyloid precursor protein/presenilin 1 mouse model of Alzheimer's disease. Journal of Molecular Neuroscience : Mn. 41: 114-20. PMID 19844808 DOI: 10.1007/s12031-009-9300-x  0.48
2010 Bassan H, Kidron D, Bassan M, Rotstein M, Kariv N, Giladi E, Davidson A, Gozes I, Harel S. The effects of vascular intrauterine growth retardation on cortical astrocytes. The Journal of Maternal-Fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians. 23: 595-600. PMID 19757337 DOI: 10.1080/14767050903197068  0.48
2010 Naor Z, Gozes I. Fifth International Symposium on Signal Transduction in Health and Disease (STADY V) Molecular and Cellular Endocrinology. 314: 157. DOI: 10.1016/j.mce.2009.07.009  0.48
2009 Gozes I, Stewart A, Morimoto B, Fox A, Sutherland K, Schmeche D. Addressing Alzheimer's disease tangles: from NAP to AL-108. Current Alzheimer Research. 6: 455-60. PMID 19874271 DOI: 10.2174/156720509789207895  0.48
2009 Zemlyak I, Manley N, Vulih-Shultzman I, Cutler AB, Graber K, Sapolsky RM, Gozes I. The microtubule interacting drug candidate NAP protects against kainic acid toxicity in a rat model of epilepsy. Journal of Neurochemistry. 111: 1252-63. PMID 19799711 DOI: 10.1111/j.1471-4159.2009.06415.x  0.48
2009 Goldberg S, Visochek L, Giladi E, Gozes I, Cohen-Armon M. PolyADP-ribosylation is required for long-term memory formation in mammals. Journal of Neurochemistry. 111: 72-9. PMID 19645746 DOI: 10.1111/j.1471-4159.2009.06296.x  0.48
2009 Zemlyak I, Sapolsky R, Gozes I. NAP protects against cytochrome c release: inhibition of the initiation of apoptosis. European Journal of Pharmacology. 618: 9-14. PMID 19619522 DOI: 10.1016/j.ejphar.2009.07.013  0.48
2009 Zemlyak I, Sapolsky R, Gozes I. NAP protects against cyanide-related microtubule destruction. Journal of Neural Transmission (Vienna, Austria : 1996). 116: 1411-6. PMID 19551468 DOI: 10.1007/s00702-009-0252-7  0.48
2009 Shiryaev N, Jouroukhin Y, Giladi E, Polyzoidou E, Grigoriadis NC, Rosenmann H, Gozes I. NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Neurobiology of Disease. 34: 381-8. PMID 19264130 DOI: 10.1016/j.nbd.2009.02.011  0.48
2009 Koshimizu H, Senatorov V, Loh YP, Gozes I. Neuroprotective protein and carboxypeptidase E. Journal of Molecular Neuroscience : Mn. 39: 1-8. PMID 19165633 DOI: 10.1007/s12031-008-9164-5  0.48
2009 Shprung T, Gozes I. A novel method for analyzing mitochondrial movement: inhibition by paclitaxel in a pheochromocytoma cell model. Journal of Molecular Neuroscience : Mn. 37: 254-62. PMID 18636346 DOI: 10.1007/s12031-008-9129-8  0.48
2008 Sanchez-Ramos J, Song S, Cao C, Arendash G. The potential of hematopoietic growth factors for treatment of Alzheimer's disease: a mini-review. Bmc Neuroscience. 9: S3. PMID 19090991 DOI: 10.1186/1471-2202-9-S2-S3  0.48
2008 Malkoff A, Weizman A, Gozes I, Rehavi M. Decreased M1 muscarinic receptor density in rat amphetamine model of schizophrenia is normalized by clozapine, but not haloperidol. Journal of Neural Transmission (Vienna, Austria : 1996). 115: 1563-71. PMID 18806925 DOI: 10.1007/s00702-008-0122-8  0.48
2008 Gozes I. VIP, from gene to behavior and back: summarizing my 25 years of research. Journal of Molecular Neuroscience : Mn. 36: 115-24. PMID 18607776 DOI: 10.1007/s12031-008-9105-3  0.48
2008 Shioda S, Vaudry H, May V, Braas K, Reglodi D, Gozes I. In memory of our teacher, Dr. Akira Arimura. Journal of Molecular Neuroscience : Mn. 36: 3-7. PMID 18607775 DOI: 10.1007/s12031-008-9107-1  0.48
2008 May V, Parsons RL, Gozes I. 8th international symposium on VIP, PACAP related peptides. Introduction. Journal of Molecular Neuroscience : Mn. 36: 1-2. PMID 18551257 DOI: 10.1007/s12031-008-9106-2  0.48
2008 Jehle T, Dimitriu C, Auer S, Knoth R, Vidal-Sanz M, Gozes I, Lagrèze WA. The neuropeptide NAP provides neuroprotection against retinal ganglion cell damage after retinal ischemia and optic nerve crush. Graefe's Archive For Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv FüR Klinische Und Experimentelle Ophthalmologie. 246: 1255-63. PMID 18414890 DOI: 10.1007/s00417-007-0746-7  0.48
2008 Mandel S, Spivak-Pohis I, Gozes I. ADNP differential nucleus/cytoplasm localization in neurons suggests multiple roles in neuronal differentiation and maintenance. Journal of Molecular Neuroscience : Mn. 35: 127-41. PMID 18286385 DOI: 10.1007/s12031-007-9013-y  0.48
2008 Matsuoka Y, Jouroukhin Y, Gray AJ, Ma L, Hirata-Fukae C, Li HF, Feng L, Lecanu L, Walker BR, Planel E, Arancio O, Gozes I, Aisen PS. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. The Journal of Pharmacology and Experimental Therapeutics. 325: 146-53. PMID 18199809 DOI: 10.1124/jpet.107.130526  0.48
2008 Kushnir M, Dresner E, Mandel S, Gozes I. Silencing of the ADNP-family member, ADNP2, results in changes in cellular viability under oxidative stress. Journal of Neurochemistry. 105: 537-45. PMID 18179478 DOI: 10.1111/j.1471-4159.2007.05173.x  0.48
2008 Dangoor D, Biondi B, Gobbo M, Vachutinski Y, Fridkin M, Gozes I, Rocchi R. Novel glycosylated VIP analogs: synthesis, biological activity, and metabolic stability. Journal of Peptide Science : An Official Publication of the European Peptide Society. 14: 321-8. PMID 17924396 DOI: 10.1002/psc.932  0.48
2007 Gozes I, Divinski I. NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell. Current Alzheimer Research. 4: 507-9. PMID 18220512 DOI: 10.2174/156720507783018208  0.48
2007 Giladi E, Hill JM, Dresner E, Stack CM, Gozes I. Vasoactive intestinal peptide (VIP) regulates activity-dependent neuroprotective protein (ADNP) expression in vivo. Journal of Molecular Neuroscience : Mn. 33: 278-83. PMID 17952637 DOI: 10.1007/s12031-007-9003-0  0.48
2007 Mandel S, Gozes I. Activity-dependent neuroprotective protein constitutes a novel element in the SWI/SNF chromatin remodeling complex. The Journal of Biological Chemistry. 282: 34448-56. PMID 17878164 DOI: 10.1074/jbc.M704756200  0.48
2007 Hill JM, Hauser JM, Sheppard LM, Abebe D, Spivak-Pohis I, Kushnir M, Deitch I, Gozes I. Blockage of VIP during mouse embryogenesis modifies adult behavior and results in permanent changes in brain chemistry. Journal of Molecular Neuroscience : Mn. 31: 183-200. PMID 17726225  0.48
2007 Vulih-Shultzman I, Pinhasov A, Mandel S, Grigoriadis N, Touloumi O, Pittel Z, Gozes I. Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. The Journal of Pharmacology and Experimental Therapeutics. 323: 438-49. PMID 17720885 DOI: 10.1124/jpet.107.129551  0.48
2007 Stewart AJ, Fox A, Morimoto BH, Gozes I. Looking for novel ways to treat the hallmarks of Alzheimer's disease. Expert Opinion On Investigational Drugs. 16: 1183-96. PMID 17685868 DOI: 10.1517/13543784.16.8.1183  0.48
2007 Gozes I. The role of vasoactive intestinal peptide in neuroprotection: Professor Illana Gozes is interviewed by Emma Quigley. Expert Opinion On Therapeutic Targets. 11: 733-6. PMID 17504011 DOI: 10.1517/14728222.11.6.733  0.48
2007 Dangoor D, Rubinraut S, Fridkin M, Gozes I. Novel analogs of VIP with multiple C-terminal domains. Peptides. 28: 1622-30. PMID 17481779 DOI: 10.1016/j.peptides.2007.03.014  0.48
2007 Moody TW, Gozes I. Vasoactive intestinal peptide receptors: a molecular target in breast and lung cancer. Current Pharmaceutical Design. 13: 1099-104. PMID 17430173 DOI: 10.2174/138161207780619000  0.48
2007 Busciglio J, Pelsman A, Helguera P, Ashur-Fabian O, Pinhasov A, Brenneman DE, Gozes I. NAP and ADNF-9 protect normal and Down's syndrome cortical neurons from oxidative damage and apoptosis. Current Pharmaceutical Design. 13: 1091-8. PMID 17430172 DOI: 10.2174/138161207780618957  0.48
2007 Gozes I. Activity-dependent neuroprotective protein: from gene to drug candidate. Pharmacology & Therapeutics. 114: 146-54. PMID 17363064 DOI: 10.1016/j.pharmthera.2007.01.004  0.48
2007 Mandel S, Rechavi G, Gozes I. Activity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin to regulate genes essential for embryogenesis. Developmental Biology. 303: 814-24. PMID 17222401 DOI: 10.1016/j.ydbio.2006.11.039  0.48
2007 Gozes I, Tiong J. From concept to potential therapeutics: Neuroprotective peptides Handbook of Neurochemistry and Molecular Neurobiology: Neural Protein Metabolism and Function. 673-688. DOI: 10.1007/978-0-387-30379-6_24  0.48
2006 Dangoor D, Rubinraut S, Fridkin M, Gozes I. Novel extended and branched N-terminal analogs of VIP. Regulatory Peptides. 137: 42-9. PMID 16962672 DOI: 10.1016/j.regpep.2006.02.010  0.48
2006 Pilzer I, Gozes I. VIP provides cellular protection through a specific splice variant of the PACAP receptor: a new neuroprotection target. Peptides. 27: 2867-76. PMID 16905223 DOI: 10.1016/j.peptides.2006.06.007  0.48
2006 Divinski I, Holtser-Cochav M, Vulih-Schultzman I, Steingart RA, Gozes I. Peptide neuroprotection through specific interaction with brain tubulin. Journal of Neurochemistry. 98: 973-84. PMID 16893427 DOI: 10.1111/j.1471-4159.2006.03936.x  0.48
2006 Quintana FJ, Zaltzman R, Fernandez-Montesinos R, Herrera JL, Gozes I, Cohen IR, Pozo D. NAP, a peptide derived from the activity-dependent neuroprotective protein, modulates macrophage function. Annals of the New York Academy of Sciences. 1070: 500-6. PMID 16888216 DOI: 10.1196/annals.1317.069  0.48
2006 Pilzer I, Gozes I. A splice variant to PACAP receptor that is involved in spermatogenesis is expressed in astrocytes. Annals of the New York Academy of Sciences. 1070: 484-90. PMID 16888214 DOI: 10.1196/annals.1317.067  0.48
2006 Gozes I, Spivak-Pohis I. Neurotrophic effects of the peptide NAP: a novel neuroprotective drug candidate. Current Alzheimer Research. 3: 197-9. PMID 16842095 DOI: 10.2174/156720506777632790  0.48
2006 Rotstein M, Bassan H, Kariv N, Speiser Z, Harel S, Gozes I. NAP enhances neurodevelopment of newborn apolipoprotein E-deficient mice subjected to hypoxia. The Journal of Pharmacology and Experimental Therapeutics. 319: 332-9. PMID 16822898 DOI: 10.1124/jpet.106.106898  0.48
2006 Steingart RA, Gozes I. Recombinant activity-dependent neuroprotective protein protects cells against oxidative stress. Molecular and Cellular Endocrinology. 252: 148-53. PMID 16704895 DOI: 10.1016/j.mce.2006.03.029  0.48
2006 Holtser-Cochav M, Divinski I, Gozes I. Tubulin is the target binding site for NAP-related peptides: ADNF-9, D-NAP, and D-SAL. Journal of Molecular Neuroscience : Mn. 28: 303-7. PMID 16691018 DOI: 10.1385/JMN:28:3:303  0.48
2006 Sari Y, Gozes I. Brain deficits associated with fetal alcohol exposure may be protected, in part, by peptides derived from activity-dependent neurotrophic factor and activity-dependent neuroprotective protein. Brain Research Reviews. 52: 107-18. PMID 16488478 DOI: 10.1016/j.brainresrev.2006.01.004  0.48
2006 Gozes I, Brenneman D. Editorial Neuropeptides. 40: 417. DOI: 10.1016/j.npep.2006.09.047  0.48
2006 Gozes I. VIP- And PACAP-Related Neuroprotection Handbook of Biologically Active Peptides. 1379-1384. DOI: 10.1016/B978-012369442-3/50195-1  0.48
2006 Gozes I. NAP: A novel candidate for AD Research and Practice in Alzheimer's Disease. 11: 392-395.  0.48
2005 Gozes I, Morimoto BH, Tiong J, Fox A, Sutherland K, Dangoor D, Holser-Cochav M, Vered K, Newton P, Aisen PS, Matsuoka Y, van Dyck CH, Thal L. NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). Cns Drug Reviews. 11: 353-68. PMID 16614735 DOI: 10.1111/j.1527-3458.2005.tb00053.x  0.48
2005 Bassan H, Bassan M, Pinhasov A, Kariv N, Giladi E, Gozes I, Harel S. The pregnant spontaneously hypertensive rat as a model of asymmetric intrauterine growth retardation and neurodevelopmental delay. Hypertension in Pregnancy. 24: 201-11. PMID 16263593 DOI: 10.1080/10641950500281142  0.48
2005 Visochek L, Steingart RA, Vulih-Shultzman I, Klein R, Priel E, Gozes I, Cohen-Armon M. PolyADP-ribosylation is involved in neurotrophic activity. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 7420-8. PMID 16093393 DOI: 10.1523/JNEUROSCI.0333-05.2005  0.48
2005 Zaltzman R, Alexandrovich A, Trembovler V, Shohami E, Gozes I. The influence of the peptide NAP on Mac-1-deficient mice following closed head injury. Peptides. 26: 1520-7. PMID 16042992 DOI: 10.1016/j.peptides.2005.03.014  0.48
2005 Dangoor D, Giladi E, Fridkin M, Gozes I. Neuropeptide receptor transcripts are expressed in the rat clitoris and oscillate during the estrus cycle in the rat vagina. Peptides. 26: 2579-84. PMID 16023261 DOI: 10.1016/j.peptides.2005.06.005  0.48
2005 Gozes I, Zaltzman R, Hauser J, Brenneman DE, Shohami E, Hill JM. The expression of activity-dependent neuroprotective protein (ADNP) is regulated by brain damage and treatment of mice with the ADNP derived peptide, NAP, reduces the severity of traumatic head injury. Current Alzheimer Research. 2: 149-53. PMID 15974912 DOI: 10.2174/1567205053585873  0.48
2005 Smith-Swintosky VL, Gozes I, Brenneman DE, D'Andrea MR, Plata-Salaman CR. Activity-dependent neurotrophic factor-9 and NAP promote neurite outgrowth in rat hippocampal and cortical cultures. Journal of Molecular Neuroscience : Mn. 25: 225-38. PMID 15800376 DOI: 10.1385/JMN:25:3:225  0.48
2005 Zawilska JB, Dejda A, Niewiadomski P, Gozes I, Nowak JZ. Receptors for VIP and PACAP in guinea pig cerebral cortex: effects on cyclic AMP synthesis and characterization by 125I-VIP binding. Journal of Molecular Neuroscience : Mn. 25: 215-24. PMID 15800375 DOI: 10.1385/JMN:25:3:215  0.48
2005 Lagrèze WA, Pielen A, Steingart R, Schlunck G, Hofmann HD, Gozes I, Kirsch M. The peptides ADNF-9 and NAP increase survival and neurite outgrowth of rat retinal ganglion cells in vitro. Investigative Ophthalmology & Visual Science. 46: 933-8. PMID 15728550 DOI: 10.1167/iovs.04-0766  0.48
2005 Furman S, Hill JM, Vulih I, Zaltzman R, Hauser JM, Brenneman DE, Gozes I. Sexual dimorphism of activity-dependent neuroprotective protein in the mouse arcuate nucleus. Neuroscience Letters. 373: 73-8. PMID 15555780 DOI: 10.1016/j.neulet.2004.09.077  0.48
2005 Gozes I, Vulih I, Spivak-Pohis I. Neuroendocrine aspects of the molecular chaperones ADNF and ADNP Molecular Chaperones and Cell Signalling. 251-262. DOI: 10.1017/CBO9780511546310.016  0.48
2005 Gozes I, Brenneman DE. Summer Neuropeptide Conference: The 14th Annual Meeting of the Summer Neuropeptide Conference, Miami Beach, Florida, USA, July 5-9, 2004 Neuropeptides. 39: 29-33. DOI: 10.1016/j.npep.2004.09.001  0.48
2004 Furman S, Steingart RA, Mandel S, Hauser JM, Brenneman DE, Gozes I. Subcellular localization and secretion of activity-dependent neuroprotective protein in astrocytes. Neuron Glia Biology. 1: 193-9. PMID 16845437 DOI: 10.1017/S1740925X05000013  0.48
2004 Gozes I, Divinski I. The femtomolar-acting NAP interacts with microtubules: Novel aspects of astrocyte protection. Journal of Alzheimer's Disease : Jad. 6: S37-41. PMID 15665412  0.48
2004 Gozes I. Parkinson's and Alzheimer's diseases: protein aggregations and neuroprotection. Journal of Molecular Neuroscience : Mn. 24: 333-6. PMID 15655257 DOI: 10.1385/JMN:24:3:333  0.48
2004 Aracil A, Belmonte C, Caló G, Gallar J, Gozes I, Hoyer D, Patachini R, Schmidt RF, Zimmermann M. Proceedings of Neuropeptides 2004, the XIV European Neuropeptides Club meeting. Neuropeptides. 38: 369-71. PMID 15651126 DOI: 10.1016/j.npep.2004.09.008  0.48
2004 Gozes I, Furman S. Clinical endocrinology and metabolism. Potential clinical applications of vasoactive intestinal peptide: a selected update. Best Practice & Research. Clinical Endocrinology & Metabolism. 18: 623-40. PMID 15533779 DOI: 10.1016/j.beem.2004.08.006  0.48
2004 Zusev M, Gozes I. Differential regulation of activity-dependent neuroprotective protein in rat astrocytes by VIP and PACAP. Regulatory Peptides. 123: 33-41. PMID 15518891 DOI: 10.1016/j.regpep.2004.05.021  0.48
2004 Zaltzman R, Alexandrovich A, Beni SM, Trembovler V, Shohami E, Gozes I. Brain injury-dependent expression of activity-dependent neuroprotective protein. Journal of Molecular Neuroscience : Mn. 24: 181-7. PMID 15456931 DOI: 10.1385/JMN:24:2:181  0.48
2004 Gozes I, Steingart RA, Spier AD. NAP mechanisms of neuroprotection Journal of Molecular Neuroscience. 24: 67-72. PMID 15314252  0.48
2004 Gozes I. Apolipoprotein E knockout mice as a model of behavioral dysfunction: A note from the editor-in-chief Journal of Molecular Neuroscience. 23: 149-150. PMID 15181242 DOI: 10.1385/JMN:23:3:149  0.48
2004 Alcalay RN, Giladi E, Pick CG, Gozes I. Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze Neuroscience Letters. 361: 128-131. PMID 15135910 DOI: 10.1016/j.neulet.2003.12.005  0.48
2004 Divinski I, Mittelman L, Gozes I. A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication Journal of Biological Chemistry. 279: 28531-28538. PMID 15123709 DOI: 10.1074/jbc.M403197200  0.48
2004 Brenneman DE, Spong CY, Hauser JM, Abebe D, Pinhasov A, Golian T, Gozes I. Protective peptides that are orally active and mechanistically nonchiral Journal of Pharmacology and Experimental Therapeutics. 309: 1190-1197. PMID 15007105 DOI: 10.1124/jpet.103.063891  0.48
2004 Gozes I. Neuropeptides 2003 Journal of Molecular Neuroscience. 22: 1-2. DOI: 10.1385/JMN:22:1-2:1  0.48
2003 Ashur-Fabian O, Segal-Ruder Y, Skutelsky E, Brenneman DE, Steingart RA, Giladi E, Gozes I. The neuroprotective peptide NAP inhibits the aggregation of the beta-amyloid peptide Peptides. 24: 1413-1423. PMID 14706557 DOI: 10.1016/j.peptides.2003.08.005  0.48
2003 Gozes I, Divinsky I, Pilzer I, Fridkin M, Brenneman DE, Spier AD. From Vasoactive Intestinal Peptide (VIP) Through Activity-Dependent Neuroprotective Protein (ADNP) to NAP: A View of Neuroprotection and Cell Division Journal of Molecular Neuroscience. 20: 315-322. PMID 14501014 DOI: 10.1385/JMN:20:3:315  0.48
2003 Gozes I. Neuroscience collaborations meeting report: The Israel Society for Neuroscience, and the Institute of Neurosciences, Mental Health and Addiction in Canada, first joint meeting, Sunday, Dec. 15, 2002, Eilat, Israel Journal of Molecular Neuroscience. 21: 55-56. PMID 14500995 DOI: 10.1385/JMN:21:1:55  0.48
2003 Pinhasov A, Mandel S, Torchinsky A, Giladi E, Pittel Z, Goldsweig AM, Servoss SJ, Brenneman DE, Gozes I. Activity-dependent neuroprotective protein: A novel gene essential for brain formation Developmental Brain Research. 144: 83-90. PMID 12888219 DOI: 10.1016/S0165-3806(03)00162-7  0.48
2003 Gozes I, Brenneman DE. Summer neuropeptide conference. The 3rd joint meeting of the summer neuropeptide conference (13th annual meeting) and the European Neuropeptide Club (13th annual meeting) Montauk, NY, June 8-12, 2003 Neuropeptides. 37: 157-158. PMID 12860113  0.48
2003 Nowak JZ, Sedkowska P, Zawilska JB, Gozes I, Brenneman DE. Antagonism of VIP-stimulated cyclic AMP formation in chick brain Journal of Molecular Neuroscience. 20: 163-171. PMID 12794310 DOI: 10.1385/JMN:20:2:163  0.48
2003 Zaltzman R, Beni SM, Giladi E, Pinhasov A, Steingart RA, Romano J, Shohami E, Gozes I. Injections of the neuroprotective peptide NAP to newborn mice attenuate head-injury-related dysfunction in adults Neuroreport. 14: 481-484. PMID 12634508  0.48
2003 Gozes I, Furman S. VIP and drug design. Current Pharmaceutical Design. 9: 483-94. PMID 12570811 DOI: 10.2174/1381612033391667  0.48
2003 Brenneman DE, Phillips TM, Hauser J, Hill JM, Spong CY, Gozes I. Complex array of cytokines released by vasoactive intestinal peptide Neuropeptides. 37: 111-119. DOI: 10.1016/S0143-4179(03)00022-2  0.48
2003 Gozes I. Preface Current Pharmaceutical Design. 9: xxx.  0.48
2002 Zimmermann M, Brain SD, Geppetti P, Gozes I, Hoyer D, Lakomy M, Meyerhof W, Michalkiewicz M, Neumann I, Nowak JZ, Przewlocka B, Quinn J, Reeh PW, Szolcsanyi J, Wasowicz K. Report on the 12th Meeting of the European Neuropeptide Club, Olsztyn, Poland, May 22-25, 2002 Neuropeptides. 36: 446-453. PMID 14710721  0.48
2002 Gozes I. Tau as a drug target in Alzheimer's disease Journal of Molecular Neuroscience. 19: 337-338. PMID 12540061 DOI: 10.1385/JMN:19:3:337  0.48
2002 Levy A, Gal R, Granoth R, Dreznik Z, Fridkin M, Gozes I. In vitro and in vivo treatment of colon cancer by VIP antagonists Regulatory Peptides. 109: 127-133. PMID 12409224 DOI: 10.1016/S0167-0115(02)00195-7  0.48
2002 Poggi SH, Vink J, Goodwin K, Hill JM, Brenneman DE, Pinhasov A, Gozes I, Spong CY. Differential expression of embryonic and maternal activity-dependent neuroprotective protein during mouse development. American Journal of Obstetrics and Gynecology. 187: 973-6. PMID 12388989 DOI: 10.1067/mob.2002.127141  0.48
2002 Steingart RA, Heldenberg E, Pinhasov A, Brenneman DE, Fridkin M, Gozes I. A vasoactive intestinal peptide receptor analog alters the expression of homeobox genes Life Sciences. 71: 2543-2552. PMID 12270759 DOI: 10.1016/S0024-3205(02)02082-9  0.48
2002 Wollman Y, Blumberg S, Spungin A, Brenneman DE, Fridkin M, Wollman J, Iaina A, Gozes I. The increased proliferation of cultured neuroblastoma cells treated with vasoactive intestinal peptide is enhanced by simultaneous inhibition of neutral endopeptidase Regulatory Peptides. 108: 175-177. PMID 12220742  0.48
2002 Gozes I, Alcalay R, Giladi E, Pinhasov A, Furman S, Brenneman DE. NAP accelerates the performance of normal rats in the water maze. Journal of Molecular Neuroscience : Mn. 19: 167-70. PMID 12212775 DOI: 10.1007/s12031-002-0028-0  0.48
2002 Gozes I, Walker MD, Kaye AM, Littauer UZ. Protein synthesis in nuclei: when did the story start? Journal of Molecular Neuroscience : Mn. 18: 167. PMID 12059034 DOI: 10.1385/JMN:18:3:167  0.48
2002 Leker RR, Teichner A, Grigoriadis N, Ovadia H, Brenneman DE, Fridkin M, Giladi E, Romano J, Gozes I. NAP, a femtomolar-acting peptide, protects the brain against ischemic injury by reducing apoptotic death Stroke. 33: 1085-1092. PMID 11935065 DOI: 10.1161/01.STR.0000014207.05597.D7  0.48
2002 Romano J, Beni-Adani L, Nissenbaum OL, Brenneman DE, Shohami E, Gozes I. A single administration of the peptide NAP induces long-term protective changes against the consequences of head injury: Gene Atlas array analysis Journal of Molecular Neuroscience. 18: 37-45. PMID 11931348 DOI: 10.1385/JMN:18:1-2:37  0.48
2002 Moody TW, Jensen RT, Fridkin M, Gozes I. (N-stearyl, Norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist Journal of Molecular Neuroscience. 18: 29-35. PMID 11931347 DOI: 10.1385/JMN:18:1-2:29  0.48
2002 Gozes I. Neuropeptides in the new millennium: Remembering friends who are no longer with us: Shmaryahu Blumberg and Noboru Yanaihara Journal of Molecular Neuroscience. 18: 1-3. DOI: 10.1385/JMN:18:1-2:1  0.48
2002 Gozes I, Spier AD. Peptides as drug candidates against Alzheimer's disease Drug Development Research. 56: 475-481. DOI: 10.1002/ddr.10103  0.48
2001 Sharma A, Walters J, Gozes Y, Fridkin M, Brenneman D, Gozes I, Moody TW. A vasoactive intestinal peptide antagonist inhibits the growth of glioblastoma cells Journal of Molecular Neuroscience. 17: 331-339. PMID 11859929 DOI: 10.1385/JMN:17:3:331  0.48
2001 Gozes I. Alzheimer's disease: My point of view Journal of Molecular Neuroscience. 17: 269-270. PMID 11816798 DOI: 10.1385/JMN:17:2:269  0.48
2001 Gozes I. Neuroprotective peptide drug delivery and development: Potential new therapeutics Trends in Neurosciences. 24: 700-705. PMID 11718874 DOI: 10.1016/S0166-2236(00)01931-7  0.48
2001 Gozes I, Brenneman DE, Geppetti P, Kastin AJ, Mains RE, Moody TW, Seroogy K, Spier AD, Zimmermann M. Neuropeptides: brain messengers of many faces. Trends in Neurosciences. 24: 687-90. PMID 11718856 DOI: 10.1016/S0166-2236(00)02001-4  0.48
2001 Moody TW, Leyton J, Chan D, C. Brenneman D, Fridkin M, Gelber E, Levy A, Gozes I. VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells Breast Cancer Research and Treatment. 68: 55-64. PMID 11678309 DOI: 10.1023/A:1017994722130  0.48
2001 Gelber E, Granoth R, Fridkin M, Dreznik Z, Brenneman DE, Moody TW, Gozes I. A lipophilic vasoactive intestinal peptide analog enhances the antiproliferative effect of chemotherapeutic agents on cancer cell lines Cancer. 92: 2172-2180. PMID 11596035 DOI: 10.1002/1097-0142(20011015)92:8<2172::AID-CNCR1560>3.0.CO;2-4  0.48
2001 Servoss SJ, Lee SJ, Gibney G, Gozes I, Brenneman DE, Hill JM. IGF-I as a mediator of VIP/activity-dependent neurotrophic factor-stimulated embryonic growth. Endocrinology. 142: 3348-53. PMID 11459777 DOI: 10.1210/endo.142.8.8335  0.48
2001 Ashur-Fabian O, Giladi E, Furman S, Steingart RA, Wollman Y, Fridkin M, Brenneman DE, Gozes I. Vasoactive intestinal peptide and related molecules induce nitrite accumulation in the extracellular milieu of rat cerebral cortical cultures. Neuroscience Letters. 307: 167-70. PMID 11438390 DOI: 10.1016/S0304-3940(01)01954-1  0.48
2001 Spong CY, Abebe DT, Gozes I, Brenneman DE, Hill JM. Prevention of fetal demise and growth restriction in a mouse model of fetal alcohol syndrome. The Journal of Pharmacology and Experimental Therapeutics. 297: 774-9. PMID 11303069  0.48
2001 Beni-Adani L, Gozes I, Cohen Y, Assaf Y, Steingart RA, Brenneman DE, Eizenberg O, Trembolver V, Shohami E. A peptide derived from activity-dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injury in mice Journal of Pharmacology and Experimental Therapeutics. 296: 57-63. PMID 11123362  0.48
2001 Zamostiano R, Pinhasov A, Gelber E, Steingart RA, Seroussi E, Giladi E, Bassan M, Wollman Y, Eyre HJ, Mulley JC, Brenneman DE, Gozes I. Cloning and characterazation of the human activity-dependent neuroprotective protein Journal of Biological Chemistry. 276: 708-714. PMID 11013255 DOI: 10.1074/jbc.M007416200  0.48
2000 Sigalov E, Fridkin M, Brenneman DE, Gozes I. VIP-related protection against iodoacetate toxicity in pheochromocytoma (PC12) cells: A model for ischemic/hypoxic injury Journal of Molecular Neuroscience. 15: 147-154. PMID 11303779 DOI: 10.1385/JMN:15:3:147  0.48
2000 Steingart RA, Solomon B, Brenneman DE, Fridkin M, Gozes I. VIP and peptides related to activity-dependent neurotrophic factor protect PC12 cells against oxidative stress Journal of Molecular Neuroscience. 15: 137-145. PMID 11303778 DOI: 10.1385/JMN:15:3:137  0.48
2000 Gozes I, Zamostiano R, Pinhasov A, Bassan M, Giladi E, Steingart RA, Brenneman DE. A novel VIP responsive gene: Activity dependent neuroprotective protein Annals of the New York Academy of Sciences. 921: 115-118. PMID 11193814  0.48
2000 Bassan H, Leider Trejo L, Kariv N, Bassan M, Berger E, Fattal A, Gozes I, Harel S. Experimental intrauterine growth retardation alters renal development Pediatric Nephrology. 15: 192-195. PMID 11149109 DOI: 10.1007/s004670000457  0.48
2000 Zemlyak I, Furman S, Brenneman DE, Gozes I. A novel peptide prevents death in enriched neuronal cultures. Regulatory Peptides. 96: 39-43. PMID 11102650 DOI: 10.1016/S0167-0115(00)00198-1  0.48
2000 Blondel O, Collin C, McCarran WJ, Zhu S, Zamostiano R, Gozes I, Brenneman DE, McKay RD. A glia-derived signal regulating neuronal differentiation. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 20: 8012-20. PMID 11050122  0.48
2000 Brenneman DE, Spong CY, Gozes I. Protective peptides derived from novel glial proteins Biochemical Society Transactions. 28: 452-455. PMID 10961938  0.48
2000 Gozes I, Giladi E, Pinhasov A, Bardea A, Brenneman DE. Activity-dependent neurotrophic factor: Intranasal administration of femtomolar-acting peptides improve performance in a water maze Journal of Pharmacology and Experimental Therapeutics. 293: 1091-1098. PMID 10869414  0.48
2000 Granoth R, Fridkin M, Gozes I. VIP and the potent analog, stearyl-Nle17-VIP, induce proliferation of keratinocytes Febs Letters. 475: 78-83. PMID 10858492 DOI: 10.1016/S0014-5793(00)01628-8  0.48
2000 Granoth R, Fridkin M, Rubinraut S, Gozes I. VIP-derived sequences modified by N-terminal stearyl moiety induce cell death: The human keratinocyte as a model Febs Letters. 475: 71-77. PMID 10858491 DOI: 10.1016/S0014-5793(00)01629-X  0.48
2000 Gozes I, Brenneman DE. A new concept in the pharmacology of neuroprotection Journal of Molecular Neuroscience. 14: 61-68. PMID 10854037  0.48
2000 White DM, Walker S, Brenneman DE, Gozes I. CREB contributes to the increased neurite outgrowth of sensory neurons induced by vasoactive intestinal polypeptide and activity-dependent neurotrophic factor Brain Research. 868: 31-38. PMID 10841885 DOI: 10.1016/S0006-8993(00)02259-9  0.48
2000 Kim WK, Kan Y, Ganea D, Hart RP, Gozes I, Jonakait GM. Vasoactive intestinal peptide and pituitary adenylyl cyclase-activating polypeptide inhibit tumor necrosis factor-α production in injured spinal cord and in activated microglia via a cAMP-dependent pathway Journal of Neuroscience. 20: 3622-3630. PMID 10804204  0.48
2000 Offen D, Sherki Y, Melamed E, Fridkin M, Brenneman DE, Gozes I. Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease. Brain Research. 854: 257-62. PMID 10784133 DOI: 10.1016/S0006-8993(99)02375-6  0.48
1999 Gozes I, Bassan M, Zamostiano R, Pinhasov A, Davidson A, Giladi E, Perl O, Glazner GW, Brenneman DE. A novel signaling molecule for neuropeptide action: Activity-dependent neuroprotective protein Annals of the New York Academy of Sciences. 897: 125-135. PMID 10676441 DOI: 10.1111/j.1749-6632.1999.tb07884.x  0.48
1999 Hill JM, Glazner GW, Lee SJ, Gozes I, Gressens P, Brenneman DE. Vasoactive intestinal peptide regulates embryonic growth through the action of activity-dependent neurotrophic factor. Annals of the New York Academy of Sciences. 897: 92-100. PMID 10676438 DOI: 10.1111/j.1749-6632.1999.tb07881.x  0.48
1999 Brenneman DE, Hauser J, Phillips TM, Davidson A, Bassan M, Gozes I. Vasoactive intestinal peptide. Link between electrical activity and glia-mediated neurotrophism. Annals of the New York Academy of Sciences. 897: 17-26. PMID 10676432  0.48
1999 Zia H, Leyton J, Casibang M, Hau V, Brenneman D, Fridkin M, Gozes I, Moody TW. (N-Stearyl, Norleucine17) VIP hybrid inhibits the growth of pancreatic cancer cell lines Life Sciences. 66: 379-387. PMID 10670826 DOI: 10.1016/S0024-3205(99)00604-9  0.48
1999 Glazner GW, Boland A, Dresse AE, Brenneman DE, Gozes I, Mattson MP. Activity-dependent neurotrophic factor peptide (ADNF9) protects neurons against oxidative stress-induced death Journal of Neurochemistry. 73: 2341-2347. PMID 10582592 DOI: 10.1046/j.1471-4159.1999.0732341.x  0.48
1999 Eilam R, Davidson A, Gozes I, Segal M. Locomotor activity causes a rapid up-regulation of vasoactive intestinal peptide in the rat hippocampus Hippocampus. 9: 534-541. PMID 10560924 DOI: 10.1002/(SICI)1098-1063(1999)9:5<534::AID-HIPO7>3.0.CO;2-R  0.48
1999 Wang HY, Jiang X, Gozes I, Fridkin M, Brenneman DE, Ganea D. Vasoactive intestinal peptide inhibits cytokine production in T lymphocytes through cAMP-dependent and cAMP-independent mechanisms Regulatory Peptides. 84: 55-67. PMID 10535409 DOI: 10.1016/S0167-0115(99)00068-3  0.48
1999 Gozes I, Fridkinb M, Hill JM, Brenneman DE. Pharmaceutical VIP: prospects and problems. Current Medicinal Chemistry. 6: 1019-34. PMID 10519911  0.48
1999 Ashur-Fabian O, Perl O, Lilling G, Fridkin M, Gozes I. SNV, a lipophilic superactive VIP analog, acts through cGMP to promote neuronal survival Peptides. 20: 629-633. PMID 10465516 DOI: 10.1016/S0196-9781(99)00017-0  0.48
1999 Hill JM, Lee SJ, Dibbern DA, Fridkin M, Gozes I, Brenneman DE. Pharmacologically distinct vasoactive intestinal peptide binding sites: CNS localization and role in embryonic growth. Neuroscience. 93: 783-91. PMID 10465461 DOI: 10.1016/S0306-4522(99)00155-4  0.48
1999 Glazner GW, Gressens P, Lee SJ, Gibney G, Gozes I, Gozes Y, Brenneman DE, Hill JM. Activity-dependent neurotrophic factor: a potent regulator of embryonic growth and development. Anatomy and Embryology. 200: 65-71. PMID 10395007 DOI: 10.1007/s004290050260  0.48
1999 Zamostiano R, Pinhasov A, Bassan M, Perl O, Steingart RA, Atlas R, Brenneman DE, Gozes I. A femtomolar-acting neuroprotective peptide induces increased levels of heat shock protein 60 in rat cortical neurons: A potential neuroprotective mechanism Neuroscience Letters. 264: 9-12. PMID 10320001 DOI: 10.1016/S0304-3940(99)00168-8  0.48
1999 Gozes I, Perl O, Giladi E, Davidson A, Ashur-Fabian O, Rubinraut S, Fridkin M. Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: Neuroprotective drug design Proceedings of the National Academy of Sciences of the United States of America. 96: 4143-4148. PMID 10097177 DOI: 10.1073/pnas.96.7.4143  0.48
1999 Bassan M, Zamostiano R, Davidson A, Pinhasov A, Giladi E, Perl O, Bassan H, Blat C, Gibney G, Glazner G, Brenneman DE, Gozes I. Complete sequence of a novel protein containing a femtomolar-activity- dependent neuroprotective peptide Journal of Neurochemistry. 72: 1283-1293. PMID 10037502 DOI: 10.1046/j.1471-4159.1999.0721283.x  0.48
1999 Gressens P, Besse L, Robberecht P, Gozes I, Fridkin M, Evrard P. Neuroprotection of the developing brain by systemic administration of vasoactive intestinal peptide derivatives Journal of Pharmacology and Experimental Therapeutics. 288: 1207-1213. PMID 10027860  0.48
1998 Gozes I. In memory of Victor Mutt. Discoveries of biologically important peptides Journal of Molecular Neuroscience : Mn. 11: 105-108. PMID 10096036  0.48
1998 Moody TW, Leyton J, Gozes I, Lang L, Eckelman WC. VIP and breast cancer Annals of the New York Academy of Sciences. 865: 290-296. PMID 9928023 DOI: 10.1111/j.1749-6632.1998.tb11189.x  0.48
1998 Gozes I, Perl O, Zamostiano R, Rubinraut S, Fridkin M, Shochat L, Lewin LM. Multiple actions of a hybrid PACAP antagonist: neuronal cell killing and inhibition of sperm motility. Annals of the New York Academy of Sciences. 865: 266-73. PMID 9928021 DOI: 10.1111/j.1749-6632.1998.tb11187.x  0.48
1998 Brenneman DE, Glazner G, Hill JM, Hauser J, Davidson A, Gozes I. VIP neurotrophism in the central nervous system: multiple effectors and identification of a femtomolar-acting neuroprotective peptide. Annals of the New York Academy of Sciences. 865: 207-12. PMID 9928014 DOI: 10.1111/j.1749-6632.1998.tb11180.x  0.48
1998 Delgado M, Munoz-Elias EJ, Kan Y, Gozes I, Fridkin M, Brenneman DE, Gomariz RP, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor α transcriptional activation by regulating nuclear factor-kB and cAMP response element-binding protein/c-Jun Journal of Biological Chemistry. 273: 31427-31436. PMID 9813054 DOI: 10.1074/jbc.273.47.31427  0.48
1998 Brown IR, Gozes I. Stress genes in the nervous system during development and aging diseases Annals of the New York Academy of Sciences. 851: 123-128. PMID 9668614 DOI: 10.1111/j.1749-6632.1998.tb08985.x  0.48
1998 Harmar AJ, Arimura A, Gozes I, Journot L, Laburthe M, Pisegna JR, Rawlings SR, Robberecht P, Said SI, Sreedharan SP, Wank SA, Waschek JA. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacological Reviews. 50: 265-70. PMID 9647867  0.48
Show low-probability matches.